Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jiangsu Recbio Technology Co., Ltd. has successfully completed the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40, is being tested for its efficacy and safety at multiple centers in China. With the market currently dominated by GlaxoSmithKline’s Shingrix, there is significant demand for a domestic alternative like REC610.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.